伴有RUNX1-RUNX1T1的急性髓系白血病的微小残留病（MRD）监测与突变图谱：一项针对134例患者的研究 - Suppr

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.

作者信息

Höllein Alexander, Jeromin Sabine, Meggendorfer Manja, Fasan Annette, Nadarajah Niroshan, Kern Wolfgang, Haferlach Claudia, Haferlach Torsten

机构信息

MLL Munich Leukemia Laboratory, Munich, Germany.

出版信息

Leukemia. 2018 Oct;32(10):2270-2274. doi: 10.1038/s41375-018-0086-0. Epub 2018 Mar 6.

DOI:10.1038/s41375-018-0086-0

PMID:29568097

Abstract

摘要

相似文献

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.伴有RUNX1-RUNX1T1的急性髓系白血病的微小残留病（MRD）监测与突变图谱：一项针对134例患者的研究

Leukemia. 2018 Oct;32(10):2270-2274. doi: 10.1038/s41375-018-0086-0. Epub 2018 Mar 6.

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.RNA 测序作为检测核心结合因子急性髓系白血病可测量残留病的替代工具。

Sci Rep. 2020 Nov 18;10(1):20119. doi: 10.1038/s41598-020-76933-2.

The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.异基因造血干细胞移植后RUNX1-RUNX1T1转录水平的动态变化可预测t(8;21)急性髓系白血病患者的复发情况。

J Hematol Oncol. 2017 Feb 6;10(1):44. doi: 10.1186/s13045-017-0414-2.

Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.优化 RUNX1-RUNX1T1 急性髓系白血病微小残留病的临床应用

Exp Hematol. 2021 Apr;96:63-72.e3. doi: 10.1016/j.exphem.2021.01.007. Epub 2021 Jan 29.

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.伴 t(8;21)(q22;q22.1)的急性髓系白血病的可测量残留病监测：来自 AML 研究组的结果。

Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.

Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.异基因造血干细胞移植可改善基于 MRD 指导治疗的高危儿童 t（8；21）急性髓系白血病首次缓解期的预后。

BMC Cancer. 2020 Jun 15;20(1):553. doi: 10.1186/s12885-020-07043-5.

High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.高醛脱氢酶活性在 t(8;21) 急性髓系白血病患者的诊断中预测复发。

Cancer Med. 2019 Sep;8(12):5459-5467. doi: 10.1002/cam4.2422. Epub 2019 Jul 30.

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.基于基因组 DNA 上 RUNX1-RUNX1T1 融合定量的 t(8;21) 急性髓系白血病微小残留病监测。

Am J Hematol. 2014 Jun;89(6):610-5. doi: 10.1002/ajh.23696. Epub 2014 Mar 8.

Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.实时定量聚合酶链反应监测核心结合因子急性髓系白血病微小残留病对移植结果的意义。

Cancer. 2020 May 15;126(10):2183-2192. doi: 10.1002/cncr.32769. Epub 2020 Feb 26.

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.定量 RT-PCR 检测核心结合因子 AML 中的微小残留病可进行风险分层并预测复发：英国 MRC AML-15 试验的结果。

Blood. 2012 Oct 4;120(14):2826-35. doi: 10.1182/blood-2012-06-435669. Epub 2012 Aug 8.

引用本文的文献

Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics.儿童核心结合因子急性髓系白血病的分子遗传学分析

Ther Adv Hematol. 2025 Apr 16;16:20406207251330064. doi: 10.1177/20406207251330064. eCollection 2025.

Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia.核心结合因子急性髓系白血病强化诱导方案的真实世界结局

EJHaem. 2024 Jul 24;5(4):728-737. doi: 10.1002/jha2.981. eCollection 2024 Aug.

Prognostic significance of ASXL1 mutations in acute myeloid leukemia: A systematic review and meta-analysis.急性髓系白血病中ASXL1突变的预后意义：一项系统评价和荟萃分析

Caspian J Intern Med. 2024 Spring;15(2):202-214. doi: 10.22088/cjim.15.2.202.

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection.微小/可测量残留病检测中的急性髓系白血病干细胞

Cancers (Basel). 2023 May 22;15(10):2866. doi: 10.3390/cancers15102866.

Int J Hematol Oncol. 2023 Feb 14;12(1):IJH43. doi: 10.2217/ijh-2022-0004. eCollection 2023 Feb.

Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.病例报告：同种异体造血干细胞移植后伴 RUNX1-RUNX1T1 分子复发的急性髓系白血病患者采用低剂量 PD-1 阻断和阿扎胞苷进行抢先治疗。

Front Immunol. 2022 Feb 2;13:810284. doi: 10.3389/fimmu.2022.810284. eCollection 2022.

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.急性髓系白血病中的剪接因子基因突变，如果纳入当前的风险分类，具有附加价值。

Blood Adv. 2021 Sep 14;5(17):3254-3265. doi: 10.1182/bloodadvances.2021004556.

Maturation State-Specific Alternative Splicing in -ITD and NPM1 Mutated AML.-ITD和NPM1突变的急性髓系白血病中成熟状态特异性可变剪接

Cancers (Basel). 2021 Aug 4;13(16):3929. doi: 10.3390/cancers13163929.

Core binding factor acute myelogenous leukemia-2021 treatment algorithm.核心结合因子急性髓系白血病-2021 治疗算法。

Blood Cancer J. 2021 Jun 16;11(6):114. doi: 10.1038/s41408-021-00503-6.

Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.有可测量残留病与急性髓系白血病患者生存结局的关联：系统评价和荟萃分析。

JAMA Oncol. 2020 Dec 1;6(12):1890-1899. doi: 10.1001/jamaoncol.2020.4600.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献